Malignant neoplasm of prostate

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Highlighting Integration of Clinical Innovation, Multi-Omics, and AI for Solid Tumor Therapies

18 hours ago talkbio0Tagged Artificial Intelligence, CAN-2409, Candel Therapeutics, enLIGHTEN Discovery Platform, Immunotherapy, Malignant neoplasm of prostate, Multiomics, Non-Small Cell Lung Carcinoma, Precision Medicine, SITC, Solid Neoplasm

Candel Therapeutics; SITC 2025; immunotherapy; CAN-2409; multi-omics; artificial intelligence; solid tumors; enLIGHTEN Discovery Platform; prostate cancer; non-small cell lung cancer; precision medicine

GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal

1 week ago talkbio0Tagged asset, GeminiMab technology, Licensing, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, milestone payments, Oncology Pipeline, Preclinical, SmithKline Beecham, Syndivia, therapeutic autologous dendritic cells

GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset

AstraZeneca and SOPHiA GENETICS Expand AI-Powered Cancer Testing Collaboration

1 month ago talkbio0Tagged Artificial Intelligence, AstraZeneca, cancer testing, High-Throughput Nucleotide Sequencing, Malignant neoplasm of breast, Malignant neoplasm of prostate, PIK3CA/AKT1/PTEN pathway, Precision Medicine, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI; cancer testing; breast cancer; prostate cancer; next generation sequencing (NGS); PIK3CA/AKT1/PTEN pathway; real-world evidence; precision medicine

Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer

4 months ago talkbio0Tagged Astellas, BCR, biochemical recurrence, Combined Modality Therapy, EMBARK, enzalutamide, leuprolide, Malignant neoplasm of prostate, nmHSPC, non-metastatic, Overall Survival, Pfizer, Xtandi

Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)

J&J’s Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear

5 months ago talkbio0Tagged Akeega, Amplitude, Approved, BRCA, HRR gene, Inhibitor, J&J, Malignant neoplasm of prostate, mCSPC, Metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, Mutation, PARP1 gene, United States Food and Drug Administration

Akeega; J&J; prostate cancer; PARP inhibitor; FDA approval; BRCA mutations; HRR gene alterations; AMPLITUDE study; metastatic castration-sensitive prostate cancer (mCSPC); metastatic castration-resistant prostate cancer (mCRPC)

J&J Presents First Survival Data for KLK2-Targeted Bispecific Pasritamig in Prostate Cancer at ASCO 2025

5 months ago talkbio0Tagged Antibodies, Bispecific, ASCO, Human Glandular Kallikrein 2, Immunotherapy, Johnson and Johnson, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, pasritamig, survival data

Johnson & Johnson; pasritamig; bispecific antibody; ASCO 2025; prostate cancer; KLK2; metastatic castration-resistant prostate cancer (mCRPC); survival data; immunotherapy

FDA Advisory Committee Unanimously Votes Against Expanding Pfizer’s Prostate Cancer Drug Combo

6 months ago talkbio0Tagged Advisory Committees, enzalutamide, expansion, Inhibitor, Labels (device), Malignant neoplasm of prostate, mCRPC, PARP1 gene, Pfizer, talazoparib, Talzenna, unanimous vote, United States Food and Drug Administration

FDA; advisory committee; Pfizer; Talzenna; talazoparib; enzalutamide; prostate cancer; mCRPC; PARP inhibitor; label expansion; unanimous vote

MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results

8 months ago talkbio0Tagged Antibody-Drug Conjugates, CD276 gene, concerns, development aspects, discontinued, Larix, MacroGenics, Malignant neoplasm of prostate, Safety, vobra

MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns

Candel Therapeutics Sees Dramatic Stock Surge Following Successful Phase III Prostate Cancer Trial

11 months ago talkbio0Tagged Approved, CAN-2409, Candel, Malignant neoplasm of prostate, Phase 3 Clinical Trials, surge, United States Food and Drug Administration, viral immunotherapy

Candel Therapeutics, CAN-2409, Phase III trial, prostate cancer, viral immunotherapy, stock surge, FDA approval

AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback

11 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, Malignant neoplasm of prostate, Metastatic to, Phase 3 Clinical Trials, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).